Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.62−0.90 (-3.27%)
Close on Nov 18, 2026Market cap $2.97BP/E –Yield –
Amylyx Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Amylyx Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2025 was -$123.48M. For fiscal 2025 it was -$123.48M. The highest annual figure on record is $10.68M in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$123.48M | – |
| FY2024 | Dec 31, 2024 | -$167.80M | -1671.5% |
| FY2023 | Dec 31, 2023 | $10.68M | – |
| FY2022 | Dec 31, 2022 | -$182.40M | – |
| FY2021 | Dec 31, 2021 | -$75.15M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$27.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$59.03M | -547.4% |
| Q3 FY2024 | Sep 30, 2024 | -$41.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$66.67M | -900.3% |
| Q1 FY2024 | Mar 31, 2024 | -$556.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $13.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.53M | – |
| Q2 FY2023 | Jun 30, 2023 | $8.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$50.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$43.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$47.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.43M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.66M | – |
See a number that looks wrong?